Oxford BioMedica could get $100 following CAR-T approval – pharmaphorum
|
Oxford BioMedica could get $100 following CAR–T approval
pharmaphorum UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis' chimeric antigen receptor T–cell (CAR-T) therapy … |
